help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, G. Y. K.
Right arrow Articles by George, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, G. Y. K.
Right arrow Articles by George, S. R.
Endocrinology Vol. 138, No. 10 4199-4206
Copyright © 1997 by The Endocrine Society


ARTICLES

Resistance of the Dopamine D2L Receptor to Desensitization Accompanies the Up-Regulation of Receptors on to the Surface of Sf9 Cells1

Gordon Y. K. Ng2, George Varghese, Hans T. Chung, Judy Trogadis, Philip Seeman, Brian F. O’Dowd and Susan R. George

Departments of Pharmacology (G.V., B.F.O., S.R.G.), Psychiatry (G.Y.K.N., P.S.), and Medicine (H.T.C., S.R.G.), University of Toronto; and the Addiction Research Foundation (B.F.O., S.R.G.), and the Eye Research Institute (J.T.), Toronto Western Hospital, Toronto, Ontario, Canada

Address all correspondence and requests for reprints to: Dr. Susan R. George, Department of Pharmacology, University of Toronto, Medical Sciences Building, Room 4358, 8 Taddle Creek Road, Toronto, Ontario, Canada M5S 1A8. E-mail: s.george{at}utoronto.ca

Dopamine D2 receptor agonists are commonly used in the control of PRL-secreting adenomas, and the sensitivity of dopamine agonists during long term therapy is exquisite. However, the molecular mechanisms responsible for the maintenance of this cellular sensitivity to dopamine agonists remain poorly understood. In the present study, we examined the agonist-induced regulation of the human D2L receptor expressed to a specific activity of ~1 pmol receptor/mg protein in Sf9 insect cells. Treatment of D2L receptor-expressing cells with dopamine for up to 3 h resulted in no detectable change in the ligand-binding properties of the receptor and a ~120-fold reduction in the potency, but not the efficacy, of D2L receptors to mediate dopamine inhibition of forskolin-stimulated adenylyl cyclase activity. This resistance of the D2L receptor to agonist-induced desensitization was accompanied by a ~28% translocation of intracellular D2L receptors to the cell surface, as quantified by cellular fractionation and radioligand binding and visualized by whole cell immunocytochemical staining and confocal microscopy. Immunoblot analysis of the P2 membrane fraction revealed that surface D2L receptors comprised monomers and dimers. Treatment of D2L receptor-expressing cells with the protein synthesis inhibitor cycloheximide significantly reduced the basal expression level of receptors, but did not block the agonist-induced up-regulation of receptors. Longer periods of dopamine exposure for 24 h brought about a small increase in surface receptor density. However, when these studies were conducted in the presence of cycloheximide, receptor density was marginally reduced, suggesting that receptor synthesis accounts for the maintenance of cellular receptor density under these conditions. We conclude that the resistance of the D2L receptor-coupled adenylyl cyclase system to agonist-induced desensitization is attributed to the up-regulation of surface receptors after the translocation of existing intracellular receptors and de novo receptor synthesis.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
C. H. So, V. Verma, B. F. O'Dowd, and S. R. George
Desensitization of the Dopamine D1 and D2 Receptor Hetero-Oligomer Mediated Calcium Signal by Agonist Occupancy of Either Receptor
Mol. Pharmacol., August 1, 2007; 72(2): 450 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. F. Lopez-Aranda, M. J. Acevedo, A. Gutierrez, P. Koulen, and Z. U. Khan
Role of a G{alpha}i2 protein splice variant in the formation of an intracellular dopamine D2 receptor pool
J. Cell Sci., July 1, 2007; 120(13): 2171 - 2178.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. H. So, G. Varghese, K. J. Curley, M. M. C. Kong, M. Alijaniaram, X. Ji, T. Nguyen, B. F. O'Dowd, and S. R. George
D1 and D2 Dopamine Receptors Form Heterooligomers and Cointernalize after Selective Activation of Either Receptor
Mol. Pharmacol., September 1, 2005; 68(3): 568 - 578.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. A. Macey, V. V. Gurevich, and K. A. Neve
Preferential Interaction between the Dopamine D2 Receptor and Arrestin2 in Neostriatal Neurons
Mol. Pharmacol., December 1, 2004; 66(6): 1635 - 1642.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. Sun, N. Ginovart, F. Ko, P. Seeman, and S. Kapur
In Vivo Evidence for Dopamine-Mediated Internalization of D2-Receptors after Amphetamine: Differential Findings with [3H]Raclopride versus [3H]Spiperone
Mol. Pharmacol., February 1, 2003; 63(2): 456 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Hillion, M. Canals, M. Torvinen, V. Casado, R. Scott, A. Terasmaa, A. Hansson, S. Watson, M. E. Olah, J. Mallol, et al.
Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2 Receptors
J. Biol. Chem., May 10, 2002; 277(20): 18091 - 18097.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Chelli and M. Alizon
Determinants of the trans-Dominant Negative Effect of Truncated Forms of the CCR5 Chemokine Receptor
J. Biol. Chem., December 7, 2001; 276(50): 46975 - 46982.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. A. Zaki, D. E. Keith Jr., J. B. Thomas, F. I. Carroll, and C. J. Evans
Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the delta -Opioid Receptor Correlates with, but Does Not Require, G Protein Activation
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1015 - 1020.
[Abstract] [Full Text]


Home page
Plant Physiol.Home page
J. R. Cohn, T. Uhm, S. Ramu, Y.-W. Nam, D.-J. Kim, R. V. Penmetsa, T. C. Wood, R. L. Denny, N. D. Young, D. R. Cook, et al.
Differential Regulation of a Family of Apyrase Genes from Medicago truncatula
Plant Physiology, April 1, 2001; 125(4): 2104 - 2119.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
N. Hukovic, M. Rocheville, U. Kumar, R. Sasi, S. Khare, and Y. C. Patel
Agonist-dependent Up-regulation of Human Somatostatin Receptor Type 1 Requires Molecular Signals in the Cytoplasmic C-tail
J. Biol. Chem., August 27, 1999; 274(35): 24550 - 24558.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
R. G. Vickery and M. von Zastrow
Distinct Dynamin-dependent and -independent Mechanisms Target Structurally Homologous Dopamine Receptors to Different Endocytic Membranes
J. Cell Biol., January 11, 1999; 144(1): 31 - 43.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
B. Adams and B. Moghaddam
Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine
J. Neurosci., July 15, 1998; 18(14): 5545 - 5554.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society